Progress in targeting therapy of cancer metastasis by CCL21/CCR7 axis.

Li Zhang; Fazhan Wang; Xiaohan Yao; Shengnan MA; Lijing Zhang; Zhihai Qin

Return

Progress in targeting therapy of cancer metastasis by CCL21/CCR7 axis.

Author: Li ZHANG ¹ ; Fazhan WANG ¹ ; Xiaohan YAO ¹ ; Shengnan MA ¹ ; Lijing ZHANG ¹ ; Zhihai QIN ¹
Author Information

1. Medical Research Center, Department of Endocrinology and Metabolism, the First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450052, Henan, China.
Publication Type:Review
Keywords: CCL21; CCR7; lymphatic metastasis; targeting therapy; tumor
MeSH: Cell Line, Tumor; Chemokine CCL21; Endothelial Cells; Humans; Lymphatic Metastasis; Neoplasms/therapy*; Receptors, CCR7/genetics*
From: Chinese Journal of Biotechnology 2020;36(12):2741-2754
CountryChina
Language:Chinese
Abstract: Metastasis is the leading cause of mortality for cancer patients, and lymphatic metastasis is one of the main ways of tumor metastasis. The role of CCL21 and its receptor CCR7 in lymphatic metastasis has been increasingly concerned in recent years. CCR7 is mainly expressed by both dendritic cells and T cells for immune responses. CCL21, the chemokine ligand for CCR7, secreted from lymphatic endothelial cells binds CCR7 and recruits immune cells toward lymphatic vessels and lymphatic nodes. CCR7 expressed tumor cells can also metastasize to lymphatic system by the similar way as immune cells. Targeting CCL21/CCR7 axis to inhibit lymphatic metastasis but remain potent anti-tumor immune response has increasingly become a spot light of tumor immunotherapy. In this review, we summarize the role of CCL21/CCR7 axis in lymphatic metastasis, as well as preclinical trials and clinical trials in targeting CCL21/CCR7 axis for tumor metastasis therapy, hoping to accelerate the progress on tumor metastasis therapy by targeting CCL21/CCR7 axis.